LOVELAND, Colo., April 14, 2011 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska") today announced that Joe Aperfine will be named Heska's Executive Vice President, Sales and Marketing. Mr. Aperfine is to join Heska from Banfield The Pet Hospital ("Banfield"), the world's largest veterinary practice owner with over 780 hospitals and 13,000 employees, where he is currently employed as Chief Learning Officer. Mr. Aperfine has been an officer of Banfield since September 2004.
"Joe will join Heska with a proven track record of success in contributing to significant revenue growth as well as profitability for the companies he has joined," said Michael McGinley, Heska's President and Chief Operating Officer. "We were impressed with the results from sales teams he has led, including improvements in productivity and effectiveness."
Mr. Aperfine was Chief Operating Officer at Merlin Digital Technology ("Merlin"), a diagnostic imaging and telemedicine business which shared management and ownership with Banfield, from September 2004 until Merlin's sale in March 2009. He was Vice President of Sales for Novartis Animal Health from May 2003 to September 2004. Mr. Aperfine was employed by IDEXX Laboratories, Inc. in various positions from March 1996 to May 2003, most recently as Director of Sales. He holds a B.S. in Engineering from the United States Military Academy and is a former U.S. Army Ranger.
The search which led to Mr. Aperfine's hiring was conducted by Spectrum Search Partners, an executive search firm based in Denver, Colorado. Spectrum was chosen to lead the search due to their extensive experience placing senior level Sales and Marketing talent across the U.S. The search was led by Spectrum's senior leadership team, including Kevin Hahn, Tom Shahnazarian and Jay Lane.
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic instruments and supplies as well as single use, point-of-care tests, pharmaceuticals and vaccines. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. In addition, factors that could affect the business and financial results of Heska generally include the following: risks related to reliance on key personnel, including the anticipated performance of such personnel; risks related to extrapolating past results to predict future performance; risks related to relying on qualitative judgments of past performance; uncertainties related to Heska's ability to market and sell its products; uncertainties related to Heska's reliance on third-party suppliers, which is significant; competition; risks related to Heska's reliance on third parties to market and sell certain of its products; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2010.